Press Releases

Press Releases

Date Title and Summary Additional Formats
Sep 29, 2020 Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal
CORAL GABLES, Fla. , Sept. 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adopted the previously reported Report and Recommendation of the Magistrate Judge, granted summary
Aug 26, 2020 KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity
Notice of Application for Judicial Review Filed Today in the Federal Court of Canada CORAL GABLES, Fla. , Aug. 26, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative
Aug 18, 2020 Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada
CORAL GABLES, Fla. , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Aug 11, 2020 Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for "Methods of Administering 3,4-Diaminopyridine"
-The allowed claims are directed to methods of treating patients with a 3,4-DAP sensitive disease comprising administering 3,4-DAP or a salt thereof to slow acetylating patients having certain mutations in each allele of the NAT2 gene CORAL GABLES, Fla. , Aug.
Aug 10, 2020 Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
- Firdapse ® Second Quarter Net Revenues of $29.6 Million - Health Canada Approves Marketing Authorization for Firdapse ® for Treating LEMS Patients - MuSK-MG Phase 3 Trial did not Achieve Statistical Significance for Primary or Secondary Endpoints - Company to Host Quarterly Conference Call at
Aug 06, 2020 Catalyst Pharmaceuticals’ Firdapse® (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS
CORAL GABLES, Fla. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Aug 03, 2020 Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders
CORAL GABLES, Fla. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Aug 03, 2020 Catalyst Pharmaceuticals to Hold Second Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 11th, 2020
CORAL GABLES, Fla. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Jul 31, 2020 Catalyst Pharmaceuticals Comments on Magistrate Judge's Report and Recommendation in its Lawsuit against the FDA
CORAL GABLES, Fla. , July 31, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the Magistrate Judge considering Catalyst's lawsuit against the FDA has filed a Report and Recommendation in which she recommends to the District Judge handling the
Jun 23, 2020 Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer
- Pete Curry has been Promoted to Vice President of Sales - Maria Pandolfo has been Promoted to Vice President of Patient Services CORAL GABLES, Fla. , June 23, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on

Displaying 1 - 10 of 21